Filtered By:
Cancer: Lymphoma
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 355 results found since Jan 2013.
CLL-390 Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study
Context: Atrial fibrillation (AF) is a recognized adverse consequence associated with all Bruton's tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, real-world time to discontinuation (TTD) and time to next treatment (TTNT) of CLL/SLL patients with a high baseline AF risk remain unknown. Objective: To describe TTNT and TTD for CLL/SLL patients who initiated a first-line (1L) or second-or-later-line (2L+) therapy with ibrutinib or other regimens, in all patients and for subsets of patients with high baseline risk of AF/AF-related events.
Source: Clinical Lymphoma, Myeloma and Leukemia - September 21, 2022 Category: Hematology Authors: Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Qing Huang, Sumeet Panjabi, Annalise Hilts, Stephanie Lu, Marie-H élène Lafeuille, Patrick Lefebvre, Michael Choi Tags: Acute Lymphoblastic Leukemia Source Type: research
Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
CONCLUSION: This study highlights that elevated baseline AF/stroke-related risk does not adversely impact TTD and TTNT outcomes associated with ibrutinib use. Additionally, TTNT was significantly longer for patients treated with ibrutinib vs. other regimens.PMID:35973891 | DOI:10.1016/j.clml.2022.07.004
Source: Clinical Lymphoma and Myeloma - August 16, 2022 Category: Cancer & Oncology Authors: Anna Narezkina Nausheen Akhter Xiaoxiao Lu Bruno Emond Sumeet Panjabi Shaun P Forbes Annalise Hilts Stephanie Liu Marie-H élène Lafeuille Patrick Lefebvre Qing Huang Michael Choi Source Type: research
Nose to brain delivery of melatonin lipidic nanocapsules as a promising post-ischemic neuroprotective therapeutic modality
Drug Deliv. 2022 Dec;29(1):2469-2480. doi: 10.1080/10717544.2022.2104405.ABSTRACTIschemic stroke accounts for about 87% of all strokes, causing long-term disability in adults, and is the second leading cause of death worldwide. In search of new therapeutic modalities, the use of neuroprotective agents loaded in nanocarriers to be delivered by noninvasive means (i.e. via intranasal route) became a popular approach. In the current study, melatonin (MEL) was loaded in lipidic nanocapsules (LNCs) prepared using the phase inversion method, and characterized in terms of size, polydispersity, zeta potential, in vitro drug release...
Source: Drug Delivery - July 27, 2022 Category: Drugs & Pharmacology Authors: Eman A Bseiso Sarah A AbdEl-Aal Maha Nasr Omaima A Sammour Nabaweya A Abd El Gawad Source Type: research
E-152 Neurointervention in the pediatric population: 18-years experience from a single center
ConclusionsAt out institution, multidisciplinary interaction allowed the treatment of a wide variety of cerebrovascular diseases in the pediatric population. Pediatric patients carry high complication risks due to frequent presence of systemic conditions, but joined experience from pediatric neurology, neurosurgery and neurointervention departments allow their treatment with optimal planning and results.Abstract E-152 Table 1Intracranial aneurysms Variable Value Age at diagnosis, mean (SD) or median (IQR) 16 (16–19) Male:Female 12:10 Associated conditions•Moya moya•Connective tissue disorder•Von Wille...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Donnelly, B., Monteiro, A., Recker, M., Khawar, W., Waqas, M., Cappuzzo, J., Reynolds, R., Siddiqui, A., Levy, E. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research
Real-World Persistence and Time to Next Treatment with Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
: Atrial fibrillation (AF) is a recognized adverse consequence associated with all Bruton's tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, real-world time to discontinuation (TTD) and time to next treatment (TTNT) of CLL/SLL patients with a high baseline AF/stroke risk remain unknown.
Source: Clinical Lymphoma, Myeloma and Leukemia - July 12, 2022 Category: Hematology Authors: Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Sumeet Panjabi, Shaun P. Forbes, Annalise Hilts, Stephanie Liu, Marie-H élène Lafeuille, Patrick Lefebvre, Qing Huang, Michael Choi Tags: Original Study Source Type: research
Optical Coherence Tomography Evaluation of Carotid Artery Stenosis and Stenting in Patients With Previous Cervical Radiotherapy
CONCLUSION: The morphological features of RICS were heterogeneous, including heterogeneous signal-rich tissue, dissection, and advanced atherosclerosis. Stenting was successful in all 5 patients with severe RICS. One patient, with high rates of tissue protrusion and stent strut malapposition immediately after stenting, received in-stent neointimal hyperplasia at a 6-month follow-up.PMID:35573285 | PMC:PMC9095735 | DOI:10.3389/fnins.2022.861511
Source: Atherosclerosis - May 16, 2022 Category: Cardiology Authors: Xiaohui Xu Feihong Huang Xuan Shi Rui Liu Yunfei Han Min Li Fang Wang Qingwen Yang Wusheng Zhu Ruidong Ye Xinfeng Liu Source Type: research
Circular RNA from phosphodiesterase 4D can attenuate chondrocyte apoptosis and matrix degradation under OA milieu induced by IL-1 β via circPDE4D/miR-4306/SOX9 cascade
CONCLUSION: CircPDE4D and miR-4306 were important regulators in regulating IL-1β-induced HNC apoptosis and matrix degradation via regulating the key transcription factor SOX9, suggesting a novel circPDE4D/miR-4306/SOX9 ceRNA pathway in OA-related chondrocyte dysfunction.PMID:35549803 | DOI:10.1080/08923973.2022.2077215
Source: Immunopharmacology and Immunotoxicology - May 13, 2022 Category: Allergy & Immunology Authors: Lixia Gao Xiaoyun Wang Jian Xiong Yan Ma Source Type: research
